SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.
Gregg Honigblum, Chief Investment Officer, and Ryan Elmore, President of SINTX, will deliver a company presentation and participate in one-on-one meetings with investors throughout the conference. The presentation will highlight SINTX’s progress in commercializing its FDA-cleared SINAPTIC® Foot & Ankle Implant System, expanding adoption of its proprietary silicon nitride technology, growing its contract manufacturing activities, and advancing strategic initiatives designed to broaden the Company’s commercial opportunities and support long-term shareholder value.
Event Details
Conference: 28th Annual H.C. Wainwright Global Investment Conference
Date: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York City
Investors interested in scheduling a one-on-one meeting with SINTX management are encouraged to contact their H.C. Wainwright representative, email meetings@hcwco.com, or contact SINTX Investor Relations at IR@sintx.com.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC® Foot & Ankle Implant System for reconstructive surgery.
SINTX Contacts:
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
